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Abstract
Objective: Glucocerebrosidase gene (GBA) variants that cause Gaucher disease
are associated with Parkinson disease (PD) and dementia with Lewy bodies
(DLB). To investigate the role of GBA variants in multiple system atrophy
(MSA), we analyzed GBA variants in a large case–control series. Methods: We
sequenced coding regions and flanking splice sites of GBA in 969 MSA patients
(574 Japanese, 223 European, and 172 North American) and 1509 control
subjects (900 Japanese, 315 European, and 294 North American). We focused
solely on Gaucher-disease-causing GBA variants. Results: In the Japanese series,
we found nine carriers among the MSA patients (1.65%) and eight carriers
among the control subjects (0.89%). In the European series, we found three
carriers among the MSA patients (1.35%) and two carriers among the control
subjects (0.63%). In the North American series, we found five carriers among
the MSA patients (2.91%) and one carrier among the control subjects (0.34%).
Subjecting each series to a Mantel–Haenszel analysis yielded a pooled odds ratio
(OR) of 2.44 (95% confidence interval [CI], 1.14–5.21) and a P-value of 0.029
without evidence of significant heterogeneity. Logistic regression analysis yielded
similar results, with an adjusted OR of 2.43 (95% CI 1.15–5.37) and a P-value
of 0.022. Subtype analysis showed that Gaucher-disease-causing GBA variants
are significantly associated with MSA cerebellar subtype (MSA-C) patients
(P = 7.3 9 103). Interpretation: The findings indicate that, as in PD and
DLB, Gaucher-disease-causing GBA variants are associated with MSA.
Introduction
Multiple system atrophy (MSA) is a progressive neurode-
generative disease characterized clinically by autonomic
failure in addition to various combinations of parkinson-
ism, cerebellar ataxia, and pyramidal dysfunction.1 The
cardinal neuropathological hallmark is argyrophilic fila-
mentous glial cytoplasmic inclusions (GCIs)2,3 in which
fibrillar aggregates of a–synuclein in oligodendrocytes are
the major components.4,5
Until recently, MSA had been defined as a nongenetic
disorder, but then several multiplex families with the
disease were described, triggering extensive fruitful searches
for susceptibility genes in case–control association stud-
ies.6,7 Subsequently, we identified a homozygous mutation
and compound heterozygous mutations of COQ2 in two
multiplex families with MSA.8 We also found a common
variant (V393A) and multiple rare variants in COQ2, all of
which lead to functional impairments in the COQ2 gene
product that increase the risk of developing sporadic MSA.
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V393A was observed exclusively in the Japanese population,
and the carrier frequency of V393A was significantly higher
in Japanese MSA patients (9.1%) than in Japanese controls
(3.3–4.4%) with odds ratios of 2.1–3.0. These findings sug-
gest that impaired COQ2 activity, which would be pre-
dicted to impair the mitochondrial respiratory chain and
increase vulnerability to oxidative stress, causes susceptibil-
ity to MSA. As the association was observed only in a small
proportion of MSA patients, the pathogenic mechanisms
underlying MSA largely remain unknown.
In contrast to the GCIs found in MSA, neuronal inclu-
sions containing a–synuclein, termed Lewy bodies (LBs),
are observed neuropathologically in Parkinson disease
(PD) and dementia with LBs (DLB).9 Abnormal fibrillar a–
synuclein aggregation in LBs and GCIs is the common fea-
ture of PD/DLB and MSA, respectively, which collectively
form a subset of neurodegenerative disorders referred to as
the “a–synucleinopathies”.10 Intriguingly, a link between
PD and MSA was reported recently based on postmortem
brain examinations of familial PD patients with SNCA
mutations (G51D and A53E) showing a–synuclein pathol-
ogy characterized by neuronal and oligodendroglial
inclusions similar to GCIs.11,12 Moreover, the risk of par-
kinsonism among first-degree relatives is significantly
higher in MSA patients than in control subjects,13,14 and
coincidence of PD and MSA within the same pedigrees has
been reported.15 Taken together, these findings raise the
possibility that MSA and PD share some genetic basis.
Glucocerebrosidase (GBA) genetic variants that have
been proven to be pathogenic for Gaucher disease (GD
variants) are strongly associated with PD and DLB.16–18
Initial focus upon GD variants came from a report of sev-
eral families of patients with GD in which obligate or
confirmed carriers frequently developed parkinsonism.19
As then, many studies have shown that GD variants are
associated with PD and DLB.16–18
In this study, we analyzed GBA in a large series of spo-
radic MSA patients and control subjects to investigate the
role of GD variants in the pathogenesis of MSA.
Methods
Patients with sporadic MSA and control
subjects
All patients with sporadic MSA and healthy control sub-
jects described in the previous reports,8,16 and additional
participants (210 MSA patients and 380 control subjects
in the Japanese series) were enrolled in this study. Writ-
ten informed consent was obtained from all participants
in accordance with research protocols that were approved
by institutional review boards at participating centers.
The diagnoses of possible and probable MSA were made
based upon current consensus criteria.1 A total of 574
patients with sporadic MSA and 900 control subjects were
included in the Japanese series, 223 patients and 315
control subjects in the European series and 172 patients
and 294 control subjects in the North American series
(persons of European or Hispanic descent living in North
America). Ancestry was determined by self-report on a
multiple-choice questionnaire. The North American series
comprised 160 persons of European descent and 12
persons of Hispanic descent in patients and 284 persons
of European descent and 10 persons of Hispanic descent
in control subjects. Among the 218 MSA patients in the
Japanese series where information on family history was
available (159 with MSA cerebellar subtype [MSA-C], 53
with MSA of the parkinsonism subtype [MSA-P] and six
with MSA of undefined subtype), there were 22 MSA
patients (11 MSA-C, 10 MSA-P, and one undefined sub-
type) who also had relatives with the clinical diagnosis of
PD. Among these relatives with PD, genomic DNAs were
available from five (in five families) who had siblings with
MSA. Sporadic MSA patients and control subjects were
recruited without reference to the presence of family
history for parkinsonism. Demographic characteristics are
shown in Table 1. In the European series, the male to
female ratio was significantly higher in cases than that in
controls (P = 0.0012). In the Japanese series, the mean
age at examination was significantly older in cases than
that in controls (P < 0.0001). The MSA-P to MSA-C
ratio was significantly higher in the North American ser-
ies than that in the Japanese series and the European ser-
ies (P < 0.0001 and P < 0.0001, respectively).
Multiplex families with MSA
Independent of the sporadic case–control series, six previ-
ously described multiplex Japanese families (1–4, 8, and 12:
same families with those in a previous report)8 were also
screened for GBA variants. Autopsy findings of two affected
members in Family 1 and III-6 in Family 8 confirmed the
diagnosis of MSA. As previously reported, affected mem-
bers in Family 1 carried the homozygous M128V-V393A
variant in COQ2 and those in Family 12 carried the com-
pound heterozygous R387X/V393A variants in COQ2.8
Nucleotide sequence analysis of GBA
Polymerase chain reaction products were subjected to
direct nucleotide sequence analysis of coding sequences
and flanking splice sites of GBA with a DNA analyzer,
3730xl (Life Technologies, Carlsbad, CA). Three primer
pairs were designed selectively to amplify GBA but not its
pseudogene, as previously described.16,20 Analysis of
sequence traces was achieved using Variant Reporter v1.1
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(Life Technologies) and by manual inspection of electro-
pherograms. All sequencing analysis was performed at the
Medical Genome Center, The University of Tokyo Hospi-
tal.
Nomenclature of GBA variants
Amino acid numbering of GBA variants followed conven-
tional nomenclature, which considers the first amino acid
after the signal peptide (the first amino acid of the
mature GBA protein) as amino acid 1.21
Gaucher-disease-causing GBA variants
We referred to the Human Gene Mutation Database
(HGMD) Professional 2014.1 (BIOBASE, Beverly, MA)
for information about GBA variants. The variants that
were categorized as “disease-causing mutations” for GD
in HGMD are hereinafter termed GD variants. In this
study, we focused solely on GD variants, which included
256 missense variants, 19 splicing variants, 28 small dele-
tions, 15 small insertions, four small indels, four gross
deletions (defined as more than 20 base-pairs), one gross
insertion, and 18 complex rearrangements.
Statistical analysis
Results are presented as means and standard deviations.
We used Student’s t-test to determine whether the mean
age at disease onset between carriers and noncarriers of
the GD variants were significantly different. We used
Fisher’s exact test and multiple logistic regression analysis
to calculate the significance of differences in allele fre-
quencies. We used multiple logistic regression analysis to
compute odds ratios and corresponding 95% confidence
intervals (CIs). We calculated pooled odds ratios based
on a fixed-effects model (Mantel–Haenszel method) and a
multiple logistic regression model. The heterogeneity
across odds ratios was assessed with Cochran Q statistic,
Breslow-Day test, and I2 statistics. All statistical tests were
two-sided, and we used a P-value of less than 0.05 to
indicate statistical significance. Our statistical analysis uti-
lized StatsDirect version 2.7.8 (StatsDirect, Cheshire, Eng-
land) and R verison 2.15.3 (http://r-project.org/).
Results
We identified 20 nonsynonymous single-nucleotide substi-
tutions and one complex multiple-nucleotide substitutions
(L444P-A456P-V460V or RecNciI) in our sporadic case–
control series. Among these 21 variants, nine were known
GD variants (R120W, G202R, F213I, N370S, G377S,
D409H, L444P, L444R, and RecNciI) (Table 2), that is, all
nine have been proven to be pathogenic for GD, which
were identified only in cases with clinical features of GD
and decreased GBA activities.22–29 The other 12 variants
have not been reported to be pathogenic for GD, and
include I(-20)V, P55L, Q57R, L67Q, R163Q, I204M,
E326K, T334I, F347L, T369M, T410R, and I489V (Table
S1). Of note, it has been shown that activities of mutant
GBA with E326K are slightly to moderately decreased. The
consensus is that E326K is not sufficient to cause GD, and a
functional polymorphism.30 With these considerations, we
did not include E326K as GD-causing mutations.
In the Japanese series, we found nine carriers of GD
variants among 574 MSA patients (1.65%) and eight car-
riers among 900 control subjects (0.89%). In the Euro-
pean series, we found three carriers among 223 MSA
patients (1.35%) and two carriers among 315 control
subjects (0.63%). In the North American series, we found
five carriers among 172 MSA patients (2.91%) and one
carrier among 294 control subjects (0.34%). Combining
all series, we identified 17 carriers among 969 MSA
patients (1.75%) as GD variant carriers, and we found
GD variant carriers in 11 of the 1509 control subjects
(0.73%). Among carriers of GD variants, two MSA
patients (one MSA-C from the European series and one
MSA-P from the North American series) carried homozy-
gous N370S variants, whereas none of the control subjects
had two alleles with GD variants. The ages at onset of the
Table 1. Demographic data of participants.
Japanese series European series North American series
MSA patients Control subjects MSA patients Control subjects MSA patients Control subjects
N 574 900 223 315 172 294
Age at onset 58.7, 8.7 NA 55.4, 8.3 NA 58.4, 9.5 NA
Age at examination 62.8, 8.3 51.1, 16.7 59.2, 8.0 58.9, 6.1 ND 65.2, 9.0
Sex (male/female) 306/268 434/466 138/85 150/165 103/69 156/138
Clinical subtype
(MSA-C/MSA-P/Undefined)
403/141/30 NA 191/22/10 NA 52/107/13 NA
Values are presented as means and standard deviations. NA, not applicable; ND, not described; MSA-C, multiple system atrophy cerebellar sub-
type; MSA-P, multiple system atrophy parkinsonism subtype.
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MSA-C and MSA-P patients were 43 and 69, respectively.
The available medical records of the two cases made no
mention of GD or relevant clinical signs.
Although the carrier frequencies of GD variants were
higher in MSA patients than in control subjects within
the three series, the difference was significant only in the
North American series (P = 0.028). A Mantel–Haenszel
procedure of each series yielded a pooled odds ratio (OR)
of 2.44 (95% CI 1.14–5.21) and a P-value of 0.029
(Fig. 1). The heterogeneity of OR of each series from the
Mantel–Haenszel analysis was not significant (Cochran
Q = 1.80, P = 0.41; Breslow-Day = 1.99, P = 0.37;
I2 = 0%). A multiple logistic regression model employing
GD variants in each series yielded an OR adjusted for
each series of 2.43 (95% CI = 1.15–5.37, P = 0.022), and
an unadjusted OR of 2.43 (95% CI = 1.15–5.37,
P = 0.022) (Table 2). Taken together, these data indicate
that there is no effect modification by the series.
We then analyzed the clinical presentations of the 17
MSA patients carrying GD variants. The ages (in years) at
symptom onset in these patients (58.1  8.2) did not differ
significantly (P = 0.93) from those in noncarriers
(57.9  8.9). The male to female ratio of these patients
(8–9) did not differ significantly (P = 0.47) from those of
noncarriers (540 to 412). The clinical phenotypes of these
17 MSA patients included 14 MSA-C and three MSA-P
subjects (Table 3). The carrier frequency of MSA-C
patients was 2.17% (14 in 646) and that of MSA-P patients
was 1.11% (3 in 270). None of the 53 patients with unde-
fined subtypes carried GD variants. Given that 11 in 1509
control subjects (0.73%) carried such variants, GD variants
were significantly associated with MSA-C (adjusted OR,
2.99 [95% CI 1.35–6.79], P = 7.3 9 103). In the MSA-C
group, a Mantel–Haenszel procedure of each series yielded
a pooled OR of 3.00 (95% CI 1.37–6.59) with a P-value of
6.3 9 103 (Fig. S1). The heterogeneity of OR of each
series from the Mantel–Haenszel analysis was not signifi-
cant (Cochran Q = 2.82, P = 0.24; Breslow-Day = 3.48,
P = 0.18; I2 = 29%). Although the carrier frequency is also
higher in MSA-P patients than in control subjects, the asso-
ciation of GD variants with MSA-P is inconclusive
(adjusted OR, 1.54 [95% CI 0.34–5.04], P = 0.51).
Interestingly, we occasionally see siblings or other fam-
ily members of the patients with MSA who are affected
with PD. Among the five sib-pairs with sporadic MSA
and PD, where genomic DNA samples are available (Fam-
ilies P2, P29, P30, P31, and P32 in Fig. 2), one sib-pair
(Family P29) share the same heterozygous GD mutation,
G202R. In another sib-pair (Family P2), one PD patient
discordantly had a heterozygous GD variant (RecNciI).
SNCA single-nucleotide substitutions and multiplications
were not present in the affected members of these pedi-
grees (data not shown).
Independent of the above analyses, we additionally
analyzed affected members in six multiplex families with
MSA reported previously.8 Of the six multiplex MSA
Table 2. Gaucher-disease-causing GBA variants in sporadic MSA patients and control subjects in each series.
Genotypes
Japanese series European series North American series
MSA patients
(n = 574)
Control subjects
(n = 900)
MSA patients
(n = 223)
Control subjects
(n = 315)
MSA patients
(n = 172)
Control subjects
(n = 294)
R120W/NM 1 0 0 0 0 0
G202R/NM 1 0 0 0 0 0
F213I/NM 2 0 0 0 0 1
N370S/NM 0 0 1 2 2 0
N370S/N370S 0 0 1 0 1 0
G377S/NM 0 0 0 0 1 0
D409H/NM 0 1 0 0 0 0
L444P/NM 4 2 1 0 1 0
L444R/NM 1 0 0 0 0 0
RecNciI/NM 0 5 0 0 0 0
Total 9/574 (1.65%) 8/900 (0.89%) 3/223 (1.35%) 2/315 (0.63%) 5/172 (2.91%) 1/294 (0.34%)
Odds ratio (95% confidence interval) 1.78 (0.68–4.76) 2.13 (0.35–16.3) 8.77 (1.34–168.8)
Fisher’s exact test P = 0.32 P = 0.65 P = 0.028
Logistic regression analysis
MSA patients (n = 969) Control subjects (n = 1509)
Carrier frequency of Gaucher-disease-causing GBA variants 17/969 (1.75%) 11/1509 (0.73%)
Odds ratio adjusted for each series (95% confidence interval) 2.43 (1.15–5.37), P = 0.022
Odds ratio unadjusted for each series (95% confidence interval) 2.43 (1.15–5.37), P = 0.022
GBA, Glucocerebrosidase; MSA, multiple system atrophy; NM, nonmutated allele.
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Figure 1. Odds ratios for GD-causing GBA variants among MSA patients, as compared with controls, at each case–control series and overall.
Shown are the combined estimates (on a log10 scale) of the odds ratios for carrying GD variants. The odds ratio estimate is marked with a solid
black square. The lines represent the 95% confidence interval of odds ratio estimate. The size of the square represents the weight that the
corresponding series exerts in the Mantel–Haenszel analysis. Confidence intervals of pooled odds ratios are displayed as a horizontal line through
the diamond. The heterogeneity of odds ratio of each series from the Mantel–Haenszel analysis was not significant (Cochran Q = 1.80, P = 0.41;
Breslow-Day = 1.99, P = 0.37; I2 = 0%), indicating that there is no effect modification by the series (population). GBA, Glucocerebrosidase; MSA,
multiple system atrophy; GD, Gaucher disease.
Table 3. Gaucher-disease-causing GBA variants in combined series in each clinical subtype.
Genotypes
Cases
Controls
MSA-C patients
(n = 646)
MSA-P patients
(n = 270)
Undefined subtypes
patients (n = 53)
Control subjects
(n = 1509)
R120W/NM 1 0 0 0
G202R/NM 1 0 0 0
F213I/NM 2 0 0 1
N370S/NM 2 1 0 0
N370S/N370S 1 1 0 2
G377S/NM 1 0 0 0
D409H/NM 0 0 0 1
L444P/NM 5 1 0 2
L444R/NM 1 0 0 0
RecNciI/NM 0 0 0 5
Total 14/646 (2.17%) 3/270 (1.11%) 0/53 (0.00%) 11/1509 (0.73%)
Adjusted odds ratio (95% confidence interval) 2.99 (1.35–6.79) 1.54 (0.34–5.04) NA NA
Fisher’s exact test P = 7.3 9 103 P = 0.51 NA NA
GBA, Glucocerebrosidase; MSA-C, multiple system atrophy of the cerebellar type; MSA-P, multiple system atrophy parkinsonism subtype; NM,
nonmutated allele; NA, not applicable.
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families, we found that three of the four patients with
MSA in Family 8 had GD variants, whereas we did not
observe GD variants in other families. In Family 8, three
patients with MSA-P (III-2, III-4, and III-6) including
one (III-6) with autopsy-proven MSA (definite MSA) had
the same heterozygous GD variant (L444R) (Fig. 3),
whereas the other patient with MSA-C (IV-1) did not
carry the variant. In addition, one unaffected sibling (III-
5) carried the variant, whereas the other unaffected sib-
ling (III-1) did not carry the variant. Thus, although co-
segregation of the GD variant with MSA was not
complete in this family, the observation may also support
some association of GD variants with MSA.
Discussion
In this study, we demonstrated that GD variants are asso-
ciated with MSA, raising a possibility that MSA, PD, and
DLB partly share genetic risk factors. The carrier fre-
quency of GD variants in MSA is 1.75% in the combined
Japanese, European, and North American series. This is
in a striking contrast to a much higher carrier frequency
of ~7% in PD, suggesting that impact of GD variants as a
risk factor for MSA is weaker compared to that for PD.17
We focused solely on GD variants that have been
reported to be pathogenic mutations for GD, and this
makes it difficult to interpret the pathogenicity of other
rare variants that have not been reported to cause GD. As
a considerable number of rare variants with unknown sig-
nificance were identified in this study, functional analysis
of each mutant GBA would be required to determine
whether they are functionally neutral variants or poten-
tially pathogenic for GD.
Diagnosis of MSA was made according to the current
consensus criteria in this study. Although there is an inher-
ent risk for clinical misdiagnosis, which would limits the
interpretations of our findings, it should also be noted that
to evaluate associations of rare variants with diseases as
encountered in this study, substantially large sample sizes
are required to accomplish a sufficient detection power.
Nonetheless, it is noteworthy that GD variants were signifi-
cantly associated with MSA-C, given that the clinical
Figure 2. Identification of Gaucher-disease-causing GBA variants in sib-pairs with coincidence of MSA and PD. Squares represent men; circles,
women; black symbols, individuals with MSA; gray symbols, individuals with PD; open symbols, unaffected individuals; dots, genomic DNAs
available. GBA, Glucocerebrosidase; MSA-C, multiple system atrophy of the cerebellar type; MSA-P, multiple system atrophy with predominant
parkinsonism; PD, Parkinson disease; NM, nonmutated allele.
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presentation of MSA-C is distinct from that of PD and
inclusion of patients with PD in the MSA-C group is unli-
kely.1 Although the carrier frequency is also higher in
MSA-P patients than in control subjects, the association of
GD variants with MSA-P is inconclusive. Given their lim-
ited sample size (n = 270) in this study, analysis of a larger
case series will be needed to answer the question of whether
GD variants are also associated with MSA-P.
In the five sib-pairs with coincidence of MSA and PD
and the six multiplex families with MSA, it is noteworthy
that, despite the low frequency of carriers of the GD vari-
ants in the Japanese controls (0.89%), GD variants were
identified, and shared by affected siblings in Family P29
(one sibling with MSA-C and one with PD) and Family 8
(three siblings with MSA-P). None of the affected individu-
als (either MSA or PD) carried deleterious variants in
COQ2 (data not shown). Although the number of families
is limited and cosegregation is not complete in Family 8,
these observations may support the increased risk of GD
variants in developing MSA, leading to familial clustering.
In our previous study, we showed that the carrier fre-
quency of V393A in COQ2 was significantly higher in
Japanese MSA patients (9.1%) than in Japanese controls
(3.3–4.4%) with odds ratios of 2.1–3.0.8 It is remarkable
that among the nine MSA patients carrying GD variants
in the Japanese series, two MSA-C patients had GD
variants (one F213I and one L444P) and V393A variants
in COQ2 simultaneously, both in heterozygous states
(data not shown). Their ages at onset were both 54 years,
which is slightly younger than the average age at onset of
58.7 years in the Japanese MSA patients. As the number
of patients carrying both alleles is limited, the biological
relevance of the combination of GBA and COQ2 variants
in the pathogenesis of MSA remains to be determined.
Previous studies have shown no significant associations
of GD variants with MSA,31–34 perhaps because of smaller
sample sizes, and perhaps because these studies analyzed
only specific variants (L444P and/or N370S). The concor-
dant trend of increased risk of GD variants for developing
MSA in each of the three series utilized in this study (Jap-
anese, European, and North American) strengthens our
conclusion and makes a bias of stratification unlikely.
Since discovery of the genetic association between GBA
and PD, the biological relationships between mutant GBA
Figure 3. Identification of Gaucher-disease-causing GBA variants in a multiplex family with MSA. The diagnosis of definite MSA in III-6 in Family
8 was confirmed by autopsy findings. Squares represent men; circles, women; black symbols, individuals with MSA; gray symbols, individuals with
PD; open symbols, unaffected individuals; dots, genomic DNAs available. GBA, Glucocerebrosidase; MSA-P, multiple system atrophy with
predominant parkinsonism; PD, Parkinson disease; NM, nonmutated allele.
424 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
GBA Mutations in Multiple System Atrophy J. Mitsui et al.
and a–synuclein have been investigated intensively. Use of
induced pluripotent stem cells from PD patients with GD
variants revealed that GBA activity was reduced, glucosyl-
ceramide and a–synuclein levels were increased, and both
autophagy and ubiquitin-proteasome pathways were
defective in derived dopaminergic neurons.35 Moreover, a
postmortem human brain study showed that, even in
sporadic PD patients without GD variants, GBA activity
was selectively reduced in the early stages of PD within
regions containing increased a–synuclein levels and lim-
ited LB formation.36 While future replication studies on
larger case–control series would be needed to verify the
association of GBA mutations with MSA, studies on the
biochemical effects associated with mutant GBA may con-
tribute to better understanding the mechanisms underly-
ing development of MSA as well as those underlying PD,
and aid in developing novel therapeutic measures for this
intractable disease.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Odds ratios for Gaucher-disease-causing GBA
variants among MSA-C patients, as compared with con-
trols, at each case–control series and overall. Shown are
the combined estimates (on a log10 scale) of the odds
ratios for carrying GD variants among MSA-C patients.
The odds ratio estimate is marked with a solid black
square. The lines represent the 95% confidence interval of
odds ratio estimate. The size of the square represents the
weight that the corresponding series exerts in the Mantel–
Haenszel analysis. Confidence intervals of pooled odds
ratios are displayed as a horizontal line through the dia-
mond. The heterogeneity of odds ratio of each series from
the Mantel–Haenszel analysis was not significant (Coch-
ran Q = 2.82, P = 0.24; Breslow-Day = 3.48, P = 0.18;
I2 = 29%), indicating that there is no effect modification
by the series (population).
Table S1. Nonsynonymous variants in GBA that have not
been reported to be causative for Gaucher disease.
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